[Clinicopathologic features, prognosis and etiology of primary non-Hodgkin lymphoma of bone].
OBJECTIVE
To study the clinicopathologic features, prognostic indicators and possible etiology of primary non-Hodgkin lymphoma of bone (PNHLB).


METHODS
The clinicopathologic features of 17 cases of PNHLB were reviewed. In-situ hybridization for Epstein-Barr virus early RNA (EBER) and polymerase chain reaction for bcl-2/JH gene rearrangement were performed using paraffin-embedded materials. The correlation between serum lactic dehydrogenase level, treatment options, international prognostic indicator (IPI) and immunophenotype with clinical outcome were analyzed.


RESULTS
The majority of the 17 cases studied was diffuse large B-cell lymphoma (94.1%). The 5-year survival rate was 68.8%. Unfavorable prognostic factors included high-risk IPI (P = 0.031) and bcl-2 overexpression (P = 0.028). Treatment options and expression of CD10, MUM-1 or bcl-6 did not correlate with clinical outcome (P > 0.05). Only 1 patient was positive for EBER, as demonstrated by in-situ hybridization.


CONCLUSIONS
The clinical outcome of PNHLB is relatively favorable. IPI and bcl-2 expression may serve as useful prognostic indicators. EBV is likely not related to pathogenesis of this type of lymphoma.
Zhou
Zhi-Yi
ZY
Department of Pathology, Nanjing University Medical College/Nanjing General Hospital of Nanjing Military Command, Nanjing 210002, China.
Shi
Qun-Li
QL
Zhou
Xiao-Jun
XJ
Lan
Jian-Yun
JY
Wang
Jian-Dong
JD
Huang
Wen-Bin
WB
Chen
Jie-Yu
JY
Ma
Heng-Hui
HH
Zhou
Hang-Bo
HB
D000293:Adolescent; D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D005260:Female; D015321:Gene Rearrangement; D019254:Genes, bcl-2; D006801:Humans; D016130:Immunophenotyping; D050835:Interferon Regulatory Factors / Q000378:metabolism; D016403:Lymphoma, Large B-Cell, Diffuse / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D015260:Neprilysin / Q000378:metabolism; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism*; D051560:Proto-Oncogene Proteins c-bcl-6 / Q000378:metabolism; D016601:RNA-Binding Proteins / Q000378:metabolism; D012269:Ribosomal Proteins / Q000378:metabolism; D015996:Survival Rate; D055815:Young Adult; D000099218:Interferon Regulatory Factor-4
D050835:Interferon Regulatory Factors; D015260:Neprilysin; D019253:Proto-Oncogene Proteins c-bcl-2; D051560:Proto-Oncogene Proteins c-bcl-6; D016601:RNA-Binding Proteins; D012269:Ribosomal Proteins; D000099218:Interferon Regulatory Factor-4; C067169:RPL22 protein, human